Carb-X

World Conference of Science Journalists
2017-10-26 08:00 - 2017-10-30 17:00 UTC
Kevin Outterson
World Conference of Science Journalists
Bridging Science and Societies
San Francisco, CA
26-30 Oct 2017

2017 BioInfect Conference - State of the Nation
2017-11-02 08:00 - 17:00 UTC
Tyler Merkeley
BioNow
2017 BioInfect Conference – State of the Nation
Cheshire, England
2 Nov 2017

Challenge Prize Center-Prize Advisory Panel Meeting
2017-11-07 08:00 - 17:00 UTC
Presenter: Kevin Outterson
Challenge Prize Center
Prize Advisory Panel Meeting
London, England
7 Nov 2017

Powered by CARB-X: How CARB-X is Accelerating Antibacterial Innovation
2017-11-08 08:00 - 17:00 UTC
Presenters:
Tyler Merkeley, Joe Larsen, Chris Houchens, Heather Shane & Lynn Marks
BARDA Industry Day
Powered by CARB-X: How CARB-X is Accelerating Antibacterial Innovation
The goal of the breakout meeting is to provide an overview on the CARB-X model and provide both industry and BARDA perspective of what it means to be “Powered by CARB-X”.
Washington DC
8 Nov 2017

Next Generation Antibiotic Workshop: Transforming Discovery
2018-01-16 08:00 - 2018-01-17 17:00 UTC
Presenters:
Kevin Outterson
John Rex
UK Catapult Conference
Next Generation Antibiotic Workshop: Transforming Discovery
London,
United Kingdom

11th Berlin Conference on Life Sciences: Novel Antimicrobial Conference and AMR Diagnostics
2018-03-02
Presenter: Kevin Outterson
BEAM Alliance
11th Berlin Conference on Life Sciences: Novel Antimicrobial Conference and AMR Diagnostics
Berlin, Germany

Innovation Gaps on Life Science Frontiers?
2018-03-05
Presenter: Kevin Outterson
NoVo Nordisk Foundation
Innovation Gaps on Life Science Frontiers? From Antimicrobial Resistance & the Bad Bugs to New Uses, AI & the Black Box
Copenhagen, Denmark

Transatlantic Taskforce on Antimicrobial Resistance
2018-03-07 08:00 - 2018-03-08 17:00 UTC
Presenter: Kevin Outterson
TATFAR
Transatlantic Taskforce on Antimicrobial Resistance
Atlanta, Georgia

Gordon Research Conference: Mechanisms Underlying Basal Ganglia Function and Dysfunction
2018-03-11 16:00 - 2018-03-16 09:00 UTC
Presenter: John Rex
Gordon Research Conference
Mechanisms Underlying Basal Ganglia Function and Dysfunction
Ventura Beach, CA
11-16 Mar 2018

CME - Superbugs and Superdrugs 2018
2018-03-19 08:30 - 2018-03-20 17:00 UTC
Presenter: Christopher Houchens
CME
Superbugs and Superdrugs 2018
London
19-20 Mar 2018

28th European Congress of Clinical Microbiology and Infectious Diseases
2018-04-21 08:00 - 2018-04-24 15:00 UTC | IFEMA – Feria de Madrid, Avda. Del Partnon 5, Madrid, ESCMID Panorama ECCMID - The Society's annual congress ESCMID's yearly congress attracts over 12'000 participants. ECCMID offers a wide range of sessions including: keynotes, symposia, poster sessions, educational workshops, meet-the-expert sessions and more. 28th ECCMID 21 – 24 April 2018 Madrid, Spain Abstract deadline 30 November 2017 Venue: IFEMA – Feria de Madrid Avda. Del Partnon 5 28042, Spain
Presenter: John Rex
ESCMID
28th European Congress of Clinical Microbiology and Infectious Diseases
Madrid, Spain
21-24 Apr 2018

Berlin Institute of Health - Charité Bih Entrepreneurship Summit
2018-05-07 08:00 - 2018-05-08 17:00 UTC | Berlin Institute of Health, Anna-Louisa-Karsch-Straße 2, Berlin, 10178, Germany
Presenter: Kevin Outterson
Berlin Institute of Health
Charité Bih Entrepreneurship Summit
Berlin, Germany
7-8 May 2018

Nature Biotechnology Conferences
2018-05-28 - 2018-05-29 | Pullman Beijing South, 12 Rong Hua Nan Lu, Beijing, 100176, China
Kevin Outterson – presentor

CARB-X welcomes on-line applications for funding of antibacterial projects
2018-06-01 00:00 - 2018-06-08 17:00 UTC | CARB-X, 765 Commonwealth Ave, Boston, MA, 02215, United States
CLICK HERE for Information on the scope of funding and how to apply

BIO International Convention 2018
2018-06-04 - 2018-06-07 | Boston Convention Center, 415 Summer St, Boston, MA, 02210, United States

ASM Microbe 2018 - Presentation by Karen Gallant
2018-06-07 08:00 - 2018-06-11 17:00 UTC | Georgia World Congress Center, 285 Andrew Young International Blvd NW, Atlanta, GA, 30313, United States

Webinar: Antibacterial Drugs: Clinical Development for Non-Developers Part 1 'Traditional development - tiers A and B
2018-06-13 17:30 - 18:30 (Europe/Berlin) | Webinar

Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics
2018-06-14 | JW Marriott Washington DC, 1331 Pennsylvania Avenue NW, Washington, DC, 20004, United States

GARDP Live Discussion Webinar: PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
2018-06-26 11:00 - 12:30 (America/New_York) | Webinar

Payment Reform Pathways for Antimicrobial Drugs: Duke-Margolis Center for Health Policy Roundtable Meeting
2018-08-09 08:30 - 12:30 (America/New_York) | Washington, DC
Facilitating Payment Reform Pathways for Antimicrobial Drugs through FDA and CMS Collaboration
As you know, the rise in antimicrobial resistant infections is a major public health threat. Few treatment options are available and the pipeline of drug candidates is extremely limited. To help address this issue, Duke-Margolis has been focused on policy initiatives that could encourage development of antimicrobial products through post-market incentives.
Participants include Kevin Outterson, Executive Director of CARB-X

FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop
2018-08-21 - 2018-08-22 | FDA White Oak Campus – Building 31, 10903 New Hampshire Ave, Silver Spring, MD, 20993, United States
The Food and Drug Administration is holding a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections.” The purpose of the public workshop is to discuss the general development considerations of non-traditional therapies, including pre-clinical development, early clinical studies, and phase 3 clinical trial designs to evaluate safety and efficacy.
Presentations by Kevin Outterson, Executive Director of CARB-X, and John Rex, Chief Medical Officer of F2G Ltd.

Next Generation Dx Summit: Investment Plenary Panel - Changing Approaches to Sustainable Funding in Diagnostics
2018-08-23 12:00 - 13:00 UTC | Grand Hyatt Washington, 1000 H St NW, Washington, DC, 20001, United States
Today, many innovators in the diagnostics industry struggle for funding, and yet news of large scale acquisitions or large (over $30M) funding rounds pops up regularly. How can innovators better understand the changing dynamics of the funding environment to succeed? How can investors know if they are getting exposed to the potentially best investments? Whether government or private, what drives the final difficult decisions and how can companies raise their chances of success? This session features leaders from several different channels of funding for innovators, including the NIH, other federal programs, and corporate and traditional venture investors.
Moderator: Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates
Panel includes Tyler Merkeley, BARDA’s CARB-X Program Manager, Health Scientist, Division of CBRN Countermeasures, BARDA.

ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
2018-09-04 08:00 - 2018-09-07 17:00 UTC | Intercontinental Lisbon, R. Castilho 149, Lisbon, 1099-024, Portugal
Drug development for AMR is a rapidly moving field. The stakes are high. A difficult riskbenefit balance must be struck. There are relatively few new classes of antibiotics and each requires highly skilled and experienced investigators to ensure these compounds reach patients. This meeting is the forum where those issues are discussed and debated.

Vaccines Against Clostridium difficile Infection (CDI): A Roadmap for the Future
2018-09-05 08:00 - 17:00 (America/New_York) | NIAID Conference Center, 5601 Fishers Lane, Rockville, MD, United States
There are 453K new C. difficile infections (CDI) every year and 83K recurrent infections, yet there are no licensed vaccines against this important nosocomial pathogen. The current pipeline of clinical-stage vaccines consists of two toxin-based candidates and one phase 3 candidate, which is no longer being pursued. Although mathematical studies and computer-simulation models suggest that a CDI vaccine would be a cost-effective approach to protect against disease, the overall public health impact for a CDI vaccine remains unclear. Moreover, there are gaps in our understanding of the mucosal immune responses against CDI and how immunity against nontoxin antigens can improve protection. This timely workshop will explore and identify high-priority knowledge gaps in C. difficile pathogenesis and immunology in order to establish a path for future CDI vaccine development, while considering the public health impact of introducing a licensed vaccine based on anti-toxin immunity.

Antibacterial drugs: Clinical development for non-developers Webinar
2018-09-11 11:00 - 12:00 (America/New_York) | Webinar
Part 2: Development of antibacterial drugs targeting specific pathogens
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In this webinar, we will discuss the development of products that target a single species of bacteria where the risks may be higher. While development of therapies for infections caused by a single bacterial species that is identified relatively frequently at a given body site of infection (e.g. Staphylococcus aureus (or even MRSA) in acute bacterial skin and skin structure infections) makes for readily feasible trials, this is not the case for infrequently occurring infections such as those caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Under these circumstances, a clinical development program can be very challenging. This webinar will give an overview of the practical challenges associated with developing a therapy for a low frequency event for which treatment must be initiated urgently. The presentation will be followed by an interactive Q&A session.

FDA Commissioner Unveils Plan to Combat Antibiotic Resistance - Live Webcast
2018-09-14 10:00 - 11:30 (America/New_York)
At least 2 million Americans a year contract an antibiotic-resistant infection, the Centers for Disease Control and Prevention reports. So, what can the U.S. do to safeguard public health amid the growing threat of these superbugs?
Tune in to a live webcast as Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, announces the agency’s plans to combat antibiotic resistance.
Following Gottlieb’s remarks, a panel of FDA senior officials will discuss aspects of the plan in more detail and take questions from the audience.

The AMR Challenge Launch Event
2018-09-25 18:00 - 21:00 (America/New_York) | The Roosevelt Hotel, 45 E 45th St, New York City, NY, 10017, United States
The AMR Challenge encourages global leaders to make formal commitments that further progress against antimicrobial resistance. Your efforts could contribute to solutions that protect humans, animals, and the environment from this global threat.
The first batch of commitments will be unveiled at a United Nations (UN) General Assembly side event on September 25, and will commence a “commitment year” that invites organizations worldwide to participate.
Attendees include Alison Haight, CARB-X Director of Finance

Antibacterial Discovery and Development Summit
2018-09-26 - 2018-09-27 | Sheraton Boston, 39 Dalton Street, Boston, MA, 02199, United States
Helping Antibacterial Development to Move Forward – New discovery platforms, novel screens and approaches are vital for the discovery of new antibacterials and for ceasing the dangerous trend of multidrug microbial resistance. Cambridge Healthtech Institute’s 5th Annual Antibacterial Discovery and Development track will focus on the general, strategic issues and solutions that would allow new antibacterial development to move forward. The conference will be held as part of the 5th Annual Re-Entering Antibacterial Discovery and Development Summit, and it will be followed by Targeting Gram-Negative Pathogens.
Kevin Outterson, Executive Director of CARB-X to speak about funding opportunities with CARB-X on September 27th at 8:25am and join the panel discussion at 10:20am.
Mark Albrecht of BARDA to speak on how BARDA is addressing the global threat of antimicrobial resistance on September 27th at 8:45am.

Grand Challenges Annual Meeting 2018
2018-10-15 - 2018-10-18 | Estrel Hotel, Sonnenallee 225, 12057 Berlin, Germany
The Grand Challenges Annual Meeting aims to accelerate the translation of innovation to impact to address the world’s most urgent global health and development problems. The meeting is a forum for researchers to share their work, learn about cutting-edge advances in the field and build collaborations with other investigators and organizations. This year the meeting will partially overlap with the 10th World Health Summit.
Hosted by the German Federal Ministry of Education & Research, Bill & Melinda Gates Foundation, Grand Challenges Canada, United States Agency for International Development, and Wellcome.
Invitation Only

Fostering Investment in the Development of New Antibacterial Treatments - UNCTAD World Investment Forum
2018-10-23 14:30 - 17:30 (America/New_York) | Palais des Nations in Geneva, 1211, Geneva, Switzerland
Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment.
